Abbott Laboratories (ABT): Total Assets
$86.71B
As of 2025-12-31
$110.43B
As of 2026-03-31
+5.2%
3-year compound annual growth
+3.6%
5-year compound annual growth
+7.7%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $86.71B | +6.5% | 2026-02-20, Balance as of period end |
| 2024-12-31 | $81.41B | +11.2% | 2026-02-20, Balance as of period end |
| 2023-12-31 | $73.21B | -1.6% | 2025-02-21, Balance as of period end |
| 2022-12-31 | $74.44B | -1.0% | 2024-02-16, Balance as of period end |
| 2021-12-31 | $75.20B | +3.6% | 2023-02-17, Balance as of period end |
| 2020-12-31 | $72.55B | +6.9% | 2022-02-18, Balance as of period end |
| 2019-12-31 | $67.89B | +1.1% | 2021-02-19, Balance as of period end |
| 2018-12-31 | $67.17B | -11.9% | 2021-02-19, Balance as of period end |
| 2017-12-31 | $76.25B | +44.8% | 2020-02-21, Balance as of period end |
| 2016-12-31 | $52.67B | +27.7% | 2019-02-22, Balance as of period end |
| 2015-12-31 | $41.25B | +0.1% | 2018-02-16, Balance as of period end |
| 2014-12-31 | $41.21B | -4.0% | 2017-02-17, Balance as of period end |
| 2013-12-31 | $42.94B | -36.1% | 2016-02-19, Balance as of period end |
| 2012-12-31 | $67.23B | +11.5% | 2015-02-27, Balance as of period end |
| 2011-12-31 | $60.28B | -0.5% | 2014-02-21, Balance as of period end |
| 2010-12-31 | $60.57B | +15.2% | 2013-02-15, Balance as of period end |
| 2009-12-31 | $52.58B | +24.0% | 2012-02-21, Balance as of period end |
| 2008-12-31 | $42.42B | +6.8% | 2011-02-18, Balance as of period end |
| 2007-12-31 | $39.71B | n/a | 2010-02-19, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $133.96B | -0.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $40.75B | +3.6% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $40.56B | +7.4% |
Compare ABT, BMY, ABBV, PFE side by side · Screen every company in Pharmaceutical Preparations ↗